Tivozanib, a cancer drug developed by AVEO Pharmaceuticals (AVEO) and Astellas Pharma, is currently under FDA review. Shares of AVEO fell by 5% today after reporting its Q4 results and offering additional details from tivozanib's phase 3 clinical trial. This news has largely been expected by investors since last summer, and health care analyst Max Macaluso breaks down what happened today in this video.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Why Shares of AVEO Hit the Brakes Today
By Max Macaluso
–
Feb 13, 2013 at 6:00PM
NASDAQ: AVEO
AVEO Pharmaceuticals
AVEO releases information regarding overall survival.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
AVEO Pharmaceuticals
AVEO
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Why AVEO Oncology Stock Is Crashing Today
Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
Why AVEO Pharmaceuticals Stock Tanked Last Month
Why AVEO Pharmaceuticals, Inc. Stock Perked Up in September
Why AVEO Pharmaceuticals Inc. Rocketed Higher Today
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.